Quantum BioPharma Expands unbuzzd™ Retail Push, Doubles Down on Bitcoin
Company builds on clinical success with unbuzzd™ rollout while adding another $1.5 million in Bitcoin to its crypto stockpile.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) isn’t standing still. The biopharmaceutical innovator behind the clinically validated alcohol detox drink, unbuzzd™, just rolled out a sleek new retail-friendly packaging format. The announcement, which helped push Quantum shares 18% higher on Wednesday, came on the heels of last week’s crypto-related news. The company reported that it boosted its cryptocurrency holdings by an additional USD $1.5 million—most notably in Bitcoin (BTCUSD)—as part of a broader treasury diversification strategy.
The company, which owns nearly 26% of Celly Nutrition, the maker of unbuzzd™, confirmed the launch of ultra-portable single-use powder sticks in convenient 8-pack display boxes. The new packaging format, which is also TSA-compliant, is intended to help facilitate the sale of unbuzzd™ in convenience, liquor and drug stores throughout the United States. Consumers can purchase the new 8-pack display box, along with packs of 3 and 18, online at unbuzzd.com and Amazon.
Big Market, Smart Design
John Duffy, CEO of Celly Nutrition and former Coca-Cola (NYSE: KO) executive, believes the compact new format will expand unbuzzd™’s retail footprint and drive profitability for sellers, stating:
The 8-pack display box enhances unbuzzd™’s package evolution, meeting various consumer needs and accelerating retail availability across the United States. This new format aims to boost sales and profits for retailers in the estimated $2.1 billion global hangover cure products market. Channel distribution at popular brick-and-mortar stores is expected to be a key growth driver for unbuzzd™ with the convenience of immediate availability for customers.
The 8-pack boxes stand out with eye-catching packaging and built-in point-of-sale features. Slim enough to slide into a purse or pocket, they offer consumers a discreet and easy-to-carry solution for nights out or long flights. That versatility is a cornerstone of Celly Nutrition’s push to dominate brick-and-mortar channels.
Gerry David, Director, Co-Chair of Celly Nutrition’s board, and former CEO of Celsius Holdings (NASDAQ: CELH) with their bestselling energy drink Celsius Energy, added:
With our recent clinical trial proving the effectiveness of unbuzzd™ in reducing blood alcohol concentration, restoring mental clarity and reducing hangover symptoms, the single-use stick in a convenient 8-pack box is an important next step in the Company’s growth, bringing unbuzzd™ to retailers and consumers in multiple formats and at an affordable price.
The updated packaging follows the product’s recent clinical trial success, a major milestone for the company.
Clinically Proven Relief
In early February, Quantum BioPharma completed a double-blind, placebo-controlled clinical trial of unbuzzd™, and the results were hard to ignore. In the study, participants who consumed the drink showed a statistically significant reduction in blood alcohol concentration (BAC) within just 30 minutes—over 40% faster than those given a placebo.
Dr. Andrzej Chruscinski, Vice President of Clinical and Scientific Affairs at Quantum BioPharma, emphasized the magnitude of the findings. “We are thrilled to see such significant and meaningful outcomes in this clinical study. This study confirms the exceptional overall performance of unbuzzd™ to help reduce the acute effects of alcohol intoxication,” he said. “We are also pleased to see that there were no product-related side effects or safety concerns in this clinical study.”
Study participants also reported improvements in alertness and cognitive performance. Physiological changes like elevated heart rate and reduced blood pressure—common symptoms of alcohol intoxication—were stabilized. Most importantly for many consumers, hangover symptoms, including headache and fatigue, significantly dropped within four to eight hours of taking the product.
Also Read: How This $4 Stock is Taking on Wall Street’s Big Banks with a $700 Million Lawsuit
Strategic Ownership and Revenue Model
Quantum BioPharma maintains a 25.71% equity stake in Celly Nutrition and holds a lucrative royalty agreement: 7% of unbuzzd™’s sales until it reaches $250 million and 3% in perpetuity thereafter. While Celly Nutrition focuses on the consumer side, Quantum holds exclusive rights to develop similar products for pharmaceutical and medical use.
Quantum CEO Zeeshan Saeed sees unbuzzd™ as more than just a commercial product—he frames it as a public health tool. “This clinical trial shows that unbuzzd™ is an important addition to the safe and responsible consumption of alcohol,” Saeed said. “Consumers now have the benefit of knowing that unbuzzd™ can reduce alcohol intoxication, speed the reduction of blood alcohol concentration, restore mental alertness and well-being, and help them avoid the worst symptoms of a hangover.”
Bitcoin Finds a Home in Quantum’s Balance Sheet
While expanding its biotech and supplement offerings, Quantum BioPharma also quietly strengthened its financial footing by buying more Bitcoin. The company revealed last week that it purchased an additional USD $1.5 million worth of Bitcoin and other cryptocurrencies, bringing its total crypto holdings to USD $3.5 million.
The move aligns with the company’s strategy to diversify its treasury and hedge against currency fluctuations. By holding crypto and enabling future financings and transactions in digital assets, Quantum positions itself at the intersection of biotech and blockchain.
All crypto assets are held with a fully compliant custodian, and the company stressed its commitment to maintaining regulatory integrity. Future crypto-related moves will depend on market conditions, with Quantum retaining the flexibility to increase or reduce its holdings as necessary.
A Modern Company for a Modern Market
Quantum BioPharma now sits at a compelling crossroads: innovating in both the wellness and financial sectors. Between the expansion of unbuzzd™, a scientifically validated product with broad market appeal, and a forward-thinking crypto treasury strategy, the company continues to carve out a unique niche.
Whether curing hangovers or hedging inflation, Quantum isn’t afraid to experiment, invest, and evolve. That makes QNTM—and even Bitcoin—worth watching.
QNTM Price Action and Chart
On a day that saw the S&P 500 (SPX) fall 1.12%, the Dow Jones Industrial Average (DJI) drop 0.31%, and the NASDAQ Composite (IXIC) slide 2.04%, Quantum BioPharma (NASDAQ: QNTM) shares were able to buck the trend, rising 18.6% to close Wednesday’s trading session at $6.95.
YTD, QNTM stock is up 70.34%.
View Quantum BioPharma Interactive Stock Chart on Barchart
Read Next: Why This Low-Float Biotech Stock Looks Ripe for Another Big Breakout
Join the Discussion in the WVC Facebook Investor Group
Do you have a stock tip or news story suggestion? Please email us at Invest@WealthyVC.com.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.
Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $20,000 for social media marketing and USD $7,500 per month for 3 months for investor relations by Quantum BioPharma Ltd.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.
In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.
